All content for Talks at GS is the property of Goldman Sachs and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
"Talks at GS" convenes leading thinkers to share insights and ideas shaping the world.
Alnylam’s Yvonne Greenstreet on RNAi and a ‘golden era’ in biotech
Talks at GS
30 minutes
5 months ago
Alnylam’s Yvonne Greenstreet on RNAi and a ‘golden era’ in biotech
Alnylam Pharmaceuticals has pioneered RNA interference therapeutics, or RNAi. This groundbreaking technology has increased the company’s success rates of bringing medicines through the clinical pipeline—leading to the approval and launch of six new medicines in just six years. Their CEO Dr. Yvonne Greenstreet spoke with Jerry Lee, head of biopharma banking in the global healthcare group, about the applications of Alnylam’s Nobel Prize-winning RNAi technology, her vision for the future of biotech, and the importance of a patient-focused and teamwork-oriented culture. Dr. Greenstreet also discussed her career journey and leadership philosophy —as one of the only women of color leading a major pharmaceutical company.
This episode was recorded on April 23, 2025.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Talks at GS
"Talks at GS" convenes leading thinkers to share insights and ideas shaping the world.
